T cells expressing a HER2-specific chimeric antigen receptor as treatment for breast cancer

被引:0
作者
Xinshan Xie
Xiaobin Li
Gang Liu
Hui Zhao
Zhenlong Zhou
Sheng Xiong
机构
[1] Jinan University,College of Life Science and Technology
[2] Institute of Biomedicine and National Engineering Research Center of Genetic Medicine,undefined
来源
Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷
关键词
CAR-T; Her2; Breast cancer cells; CD8;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:11561 / 11570
页数:9
相关论文
共 346 条
[1]  
Bang YJ(2010)Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687-697
[2]  
Van Cutsem E(2019)Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial) Breast Cancer Res Treat 176 303-310
[3]  
Feyereislova A(2015)Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T Cells in patients with recurrent glioblastoma Clin Cancer Res 21 4062-4072
[4]  
Chung HC(2014)4-1BB chimeric antigen receptors Cancer J 20 134-140
[5]  
Shen L(2002)Interleukin-12 in anti-tumor immunity and immunotherapy Cytokine Growth Factor Rev 13 155-168
[6]  
Sawaki A(2001)Herceptest: HER2 expression and gene amplification in non-small cell lung cancer Int J Cancer 92 480-483
[7]  
Lordick F(1990)Chimeric T cell receptor which incorporates the anti-tumour specificity of a monoclonal antibody with the cytolytic activity of T cells: a model system for immunotherapeutical approach Br J Cancer Suppl 10 27-29
[8]  
Ohtsu A(1996)The T-body approach: potential for cancer immunotherapy Springer Semin Immunopathol 18 199-209
[9]  
Omuro Y(1989)Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proc Natl Acad Sci USA 86 10024-10028
[10]  
Satoh T(2004)Human T regulatory cells can use the perforin pathway to cause autologous target cell death Immunity 21 589-601